Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Inclusion Criteria: * Presence of metastasized or locally advanced, unresectable (curative intent), histologically proven, well differentiated Grade 1 or Grade 2 (Ki-67 \<10%) gastroenteropancreatic neuroendocrine tumor (GEP-NET) diagnosed within 6 months prior to screening. * Participants with high disease burden in the Investigator's opinion. Following criteria should be used as the guiding principle for determining high disease burden: * Primary tumor or a metastatic lesion \> 4 cm * More than one tumor or metastatic lesions measuring \> 2 cm * Elevated alkaline phosphatase \> 2.5 X upper limit of normal (ULN) * Presence of bone metastasis * Presence of peritoneal metastasis * Symptoms due to tumor volume such as pain, fatigue, weight loss, anorexia etc. * Symptoms due to hormone excess requiring active management * Additionally, participants who, in the Investigator's opinion, have high disease burden due to their disease characteristics not specified above could also be considered eligible. * Participants ≥ 12 years of age. * RLI somatostatin receptor (SSTR) uptake on all target lesions (defined by RECIST v1.1 criteria) at least as high as normal liver uptake assessed within 3 months prior to randomization. Any of the RLI modalities as available (some examples are listed below) can be used as per local practice: * \[68Ga\]Ga-DOTA-TOC PET/CT or PET/MRI * \[68Ga\]Ga-DOTA-TATE PET/CT or PET/MRI * \[64Cu\]Cu-DOTA-TATE PET/CT or PET/MRI * Somatostat…